Edotreotide
| Names | |
|---|---|
| IUPAC name
2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
| |
| Other names
SomaKit TOC
| |
| Identifiers | |
CAS Number
|
|
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
InChI
| |
SMILES
| |
| Properties | |
Chemical formula
|
C65H92N14O18S2 |
| Molar mass | 1421.65 g·mol−1 |
| Pharmacology | |
| License data | |
| Legal status | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
| |
Edotreotide (USAN, also known as (DOTA0-Phe1-Tyr3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer.[3] When used therapeutically it is an example of peptide receptor radionuclide therapy.
- ^ "SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation - Summary of Product Characteristics (SmPC)". (emc). 2 July 2021. Retrieved 9 July 2021.
- ^ "SomaKit TOC EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 October 2020.
- ^ Martindale, The Extra Pharmacopoeia, 30th ed, p1161.